Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors

被引：0

作者：

Della-Morte, David ^{[1
,2
,3
]}

Palmirotta, Raffaele ^{[3
]}

Rehni, Ashish K. ^{[2
]}

Pastore, Donatella ^{[1
]}

Capuani, Barbara ^{[1
]}

Pacifici, Francesca ^{[1
]}

De Marchis, Maria Laura ^{[3
]}

Dave, Kunjan R. ^{[2
]}

Bellia, Alfonso ^{[1
]}

Fogliame, Giuseppe ^{[4
]}

Ferroni, Patrizia ^{[3
]}

Donadel, Giulia ^{[1
]}

Cacciatore, Francesco ^{[5
]}

Abete, Pasquale ^{[6
]}

Dong, Chuanhui ^{[2
]}

Pileggi, Antonello ^{[7
]}

Roselli, Mario ^{[1
]}

Ricordi, Camillo ^{[7
]}

Sbraccia, Paolo ^{[1
,4
]}

Guadagni, Fiorella ^{[3
]}

Rundek, Tatjana ^{[2
]}

lauro, Davide ^{[1
,4
]}

机构：

[1] Univ Roma Tor Vergata, Sch Med, Dept Syst Med, I-00133 Rome, Italy

[2] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA

[3] IRCCS San Raffaele Pisana, Interinst Multidisciplinary Biobank BioBIM, Biomarker Discovery & Adv Technol BioDAT, Rome, Italy

[4] Tor Vergata Fdn Hosp, Div Internal Med, Rome, Italy

[5] IRCCS Salvatore Maugeri, Telese Terme, BN, Italy

[6] Univ Naples Federico II, Dept Clin Med Cardiovasc Sci & Immunol, Cattedra Geriatria, Naples, Italy

[7] Univ Miami, Diabet Res Inst, Miller Sch Med, Miami, FL 33136 USA

来源：

PHARMACOGENOMICS | 2014年 / 15卷 / 16期

关键词：

cardiovascular disease; diabetes; pharmacogenetics; pharmacogenomics; single nucleotide polymorphisms; thiazolidinediones; vascular risk factors; ACTIVATED-RECEPTOR-GAMMA; ISCHEMIA-REPERFUSION INJURY; ADIPONECTIN GENE POLYMORPHISM; ORAL ANTIDIABETIC DRUGS; OBESITY-RELATED TRAITS; PPAR-GAMMA; INSULIN-RESISTANCE; CHINESE PATIENTS; ADIPOSE-TISSUE; ROSIGLITAZONE RESPONSE;

D O I：

10.2217/PGS.14.162

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The most important goal in the treatment of patients with diabetes is to prevent the risk of cardiovascular disease (CVD), the first cause of mortality in these subjects. Thiazolidinediones (TZDs), a class of antidiabetic drugs, act as insulin sensitizers increasing insulin-dependent glucose disposal and reducing hepatic glucose output. TZDs including pioglitazone, rosiglitazone and troglitazone, by activating PPAR-gamma have shown pleiotropic effects in reducing vascular risk factors and atherosclerosis. However, troglitazone was removed from the market due to its hepatoxicity, and rosiglitazone and pioglitazone both have particular warnings due to being associated with heart diseases. Specific genetic variations in genes involved in the pathways regulated by TDZs have demonstrated to modify the variability in treatment with these drugs, especially in their side effects. Therefore, pharmacogenomics and pharmacogenetics are an important tool in further understand intersubject variability per se but also to assess the therapeutic potential of such variability in drug individualization and therapeutic optimization.

引用

页码：2063 / 2082

页数：20

共 122 条

[1]

[Anonymous], COCHRANE DATABASE SY

[2] Pharmacogenetics of thiazolidinedione therapy [J].

Aquilante, Christina L. .

PHARMACOGENOMICS, 2007, 8 (08) :917-931

[3] Impact of the CYP2C8*3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone [J].

Aquilante, Christina L. ;

Kosmiski, Lisa A. ;

Bourne, David W. A. ;

Bushman, Lane R. ;

Daily, Elizabeth B. ;

Hammond, Kyle P. ;

Hopley, Charles W. ;

Kadam, Rajendra S. ;

Kanack, Alexander T. ;

Kompella, Uday B. ;

Le, Merry ;

Predhomme, Julie A. ;

Rower, Joseph E. ;

Sidhom, Maha S. .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (01) :217-226

[4] Peroxisome proliferator-activated receptor-γ represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect [J].

Armoni, M ;

Kritz, N ;

Harel, C ;

Bar-Yoseph, F ;

Chen, H ;

Quon, MJ ;

Karnieli, E .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (33) :30614-30623

[5] PPARγ, the ultimate thrifty gene [J].

Auwerx, J .

DIABETOLOGIA, 1999, 42 (09) :1033-1049

[6] Variation at the NFATC2 Locus Increases the Risk of Thiazolidinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study [J].

Bailey, Swneke D. ;

Xe, Changchun ;

Do, Ron ;

Montpetit, Alexandre ;

Diaz, Rafael ;

Mohan, Viswanathan ;

Keavney, Bernard ;

Yusuf, Salim ;

Gerstein, Hertzel C. ;

Engert, James C. ;

Anand, Sonia .

DIABETES CARE, 2010, 33 (10) :2250-2253

[7] Regulation of fasted blood glucose by resistin [J].

Banerjee, RR ;

Rangwala, SM ;

Shapiro, JS ;

Rich, AS ;

Rhoades, B ;

Qi, Y ;

Wang, J ;

Rajala, MW ;

Pocai, A ;

Scherer, PE ;

Steppan, CM ;

Ahima, RS ;

Obici, S ;

Rossetti, L ;

Lazar, MA .

SCIENCE, 2004, 303 (5661) :1195-1198

[8] The mechanisms of action of PPARs [J].

Berger, J ;

Moller, DE .

ANNUAL REVIEW OF MEDICINE, 2002, 53 :409-435

[9] PPARs: therapeutic targets for metabolic disease [J].

Berger, JP ;

Akiyama, TE ;

Meinke, PT .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2005, 26 (05) :244-251

[10] The effect of pioglitazone on peroxisome proliferator-activated receptor-γ target genes related to lipid storage in vivo [J].

Bogacka, I ;

Xie, H ;

Bray, GA ;

Smith, SR .

DIABETES CARE, 2004, 27 (07) :1660-1667

← 1 2 3 4 5 6 7 8 9 10 →